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Summary
Endothelial cells in growing tumors express activated Akt, which when modeled by transgenic endothelial expression of
myrAkt1 was sufficient to recapitulate the abnormal structural and functional features of tumor blood vessels in nontumor
tissues. Sustained endothelial Akt activation caused increased blood vessel size and generalized edema from chronic
vascular permeability, while acute permeability in response to VEGF-A was unaffected. These changes were reversible,
demonstrating an ongoing requirement for Akt signaling for the maintenance of these phenotypes. Furthermore, rapamycin
inhibited endothelial Akt signaling, vascular changes from myrAkt1, tumor growth, and tumor vascular permeability. Akt
signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth
in part by acting as a vascular Akt inhibitor.Introduction
The development and maturation of blood vessels result from
a complex interplay of pro- and antiangiogenic regulators. Dys-
regulation of the balance between these factors is thought to re-
sult in the formation of pathological blood vessels, such as those
found in tumors (Bergers and Benjamin, 2003). Tumor blood
vessels are distinctly abnormal in structure and function. While
heterogeneous, many tumor blood vessels are enlarged and tor-
tuous, and compared to normal vessels of similar sizes, they are
poorly invested by pericytes and have defective basement
membranes (Baluk et al., 2003; Carmeliet and Jain, 2000;
Morikawa et al., 2002). Tumor blood vessels are also hyper-
permeable to circulating macromolecules, partly due to the
overproduction of vascular permeability factor/vascular endo-
thelial growth factor (VPF/VEGF-A). This results in extravasation
of plasma fluid and proteins (Dvorak, 1990; Dvorak et al., 1999).
Several possible pathways by which macromolecules and other
plasma solutes cross vascular endothelium involves intercellularCANCER CELL 10, 159–170, AUGUST 2006 ª2006 ELSEVIER INC. DOI 1gaps, fenestrae, trans-endothelial cell pores, and vesiculo-vac-
uolar organelles (VVOs) (Baluk and McDonald, 1994; Feng et al.,
1999, 2000b; McDonald and Baluk, 2002).
VEGF-A is one of the major cytokines involved in tumor angio-
genesis, and its expression is regulated not only by tumor
hypoxia but also by oncogenes and tumor suppressor genes
(Harris, 2002; Pal et al., 2001; Rak et al., 1995; Rak and Kerbel,
2001; Shweiki et al., 1992). Overexpression of VEGF-A by tumor
cells leads to the formation of new blood vessels with exagger-
ated size, tortuosity, and permeability that have prolonged
dependence on VEGF-A for survival (Benjamin and Keshet,
1997). In some tumors, vessels that acquire pericyte/smooth
muscle investment are more resistant to VEGF-A deprivation
(Benjamin et al., 1999). VEGF-A overexpression has also been
shown to induce tumor-like blood vessels in normal tissues in
the absence of tumor cells (Feng et al., 2000a; Pettersson
et al., 2000; Sundberg et al., 2001).
The PI3K/Akt signaling pathway functions downstream of
VEGF-A to promote endothelial cell survival (Dimmeler andS I G N I F I C A N C E
Most of the common alterations in structure and function associated with tumor blood vessels can be recapitulated by overexpression
of VEGF-A. This study demonstrates that the Akt pathway, a key signaling pathway activated in response to VEGF-A, induces similar
structural and functional alterations. Sustained endothelial activation of Akt in otherwise healthy tissue induces vascularmalformations
and systemic vascular permeability. Moreover, the activation of Akt and the associated pathological features of the blood vessels can
be blocked by rapamycin. These findings indicate a possible clinical utility of rapamycin as an angiogenesis inhibitor and support
a pathway for rapamycin action via Akt inhibition.0.1016/j.ccr.2006.07.003 159
A R T I C L EFigure 1. Akt activation in tumor vessels
A–D: VEGF-A-expressing rat C6 glioma cells
grown subcutaneously in Nu/Nu mice were dou-
ble stained with TRITC-lectin (A, red) to label
blood vessels and anti-phosphorylated Akt anti-
body (B, green). Merged images are shown in
C, with arrows indicating endothelial cell nuclei
positive for phosphorylated Akt. Phosphorylated
Akt is also seen in tumor cells. A higher magnifica-
tion of the blood vessels within the boxed area is
shown in D.Zeiher, 2000; Fujio andWalsh, 1999;Gerber et al., 1998; Liu et al.,
2000). Recent investigation of different Akt isoforms has demon-
strated that Akt1 expression is required for pathological angio-
genesis in a hindlimb ischemia model and in response to
VEGF-A-induced acute permeability (Ackah et al., 2005). VEGF-
A-induced acute permeability is dependent on Akt signaling
and downstream activation of endothelial nitric oxide synthase
(eNOS) (Dimmeler et al., 1999; Fukumura et al., 2001; Fulton
et al., 1999; Six et al., 2002). Another downstream pathway that
has an impact on angiogenesis is the mammalian target of rapa-
mycin (mTOR) (Guba et al., 2002). Recent studies have shown
that the rapamycin-insensitive rictor-mTOR complex (mTORC2)
is the one that directly phosphorylates Akt at S473 (Sarbassov
dos et al., 2005). Despite the straightforward prediction that
rapamycin action on the raptor containing rapamycin-sensitive
complex (mTORC1) would result in increased Akt activation due
to compensatory higher levels of mTORC2, in fact, long-term
treatment of rapamycin on cells in culture decreased activation
of Akt (Edinger et al., 2003; O’Reilly et al., 2006). Investigation
of the effects of rapamycin on mTORC1 and mTORC2 com-
plexes revealed that prolonged treatment with rapamycin inter-
fereswith the formation ofmTORC2 (Sarbassov dos et al., 2006).
We have observed that tumor endothelial cells have chronic
Akt activation. To explore the function of such activation, we
have used transgenic mice that allow us to induce or repress
constitutively active myristoylated Akt1 (myrAkt1) in endothelial
cells of normal tissues to form a surrogate tumor stroma without
the complications of tumor cell contributions.We show that sus-
tained Akt activation induces the formation of enlarged, hyper-
permeable blood vessels that recapitulate the structural and
functional abnormalities of tumor vessels and mimic the effects
of VEGF-A-induced angiogenesis. Both the abnormal structure
and function were blocked by rapamycin and correlate to rapa-
mycin-induced downregulation of Akt phosphorylation in endo-
thelial cells and normal mouse tissues. Rapamycin inhibited
tumor growth and tumor vascular permeability, which we hy-
pothesize are in part due to effects of rapamycin on endothelial
Akt activation.
Results
Increased phosphorylated Akt in tumor blood vessels
We have previously shown that VEGF-A functions as a survival
factor for newly formed blood vessels and that abrupt with-
drawal of VEGF-A results in regression of tumor vessels in rat
C6 glioma cells (Benjamin and Keshet, 1997). We hypothesize160that the vasculature in tumors is abnormal in part due to chronic
activation of endothelial Akt signaling pathways as a result of
high expression of angiogenic cytokines intrinsic within the tu-
mor. Should this be correct, we would expect to see high levels
of phosphorylated Akt (pAkt) in endothelial cells lining these tu-
mor blood vessels. Immunofluorescence staining of xenografts
of rat C6 glioma cells overexpressing VEGF-A showed that
many tumor endothelial cells expressed pAkt (Figure 1). Many
tumor cells, and especially those surrounding blood vessels,
also expressed pAkt. Such perivascular cuffs of tumor cells
with activated Akt may reflect increased Akt survival signaling
in cells receiving increased oxygen and nutrients due to their
close proximity to the blood vessels. Expression of pAkt is
strong in tumor tissue but not in adjacent normal skin, and sim-
ilarly, quiescent vessels in normal skin do not show increased
activation of Akt (Figure S1 in the Supplemental Data available
with this article online).
SustainedmyrAkt1 activation in endothelial cells induces
surrogate tumor blood vessels in nontumor tissue
To mimic chronically activated Akt in tumor blood vessels in an
otherwise normal microenvironment, we used a transgenic
model of tetracycline-repressible endothelial-specific Akt acti-
vation (Sun et al., 2005). Overexpression of myrAkt1 in endothe-
lial cells results in embryonic lethality but is overcome by main-
taining mothers and their offspring on tetracycline. When the
micewere 6–8weeks of age, tetracycline waswithdrawn for var-
ious lengths of time to induce myrAkt1 expression. Endothelial
cell-specific expression of the transgene was also demon-
strated by crossing the VE-cadherin:tTA line with a reporter
strain that has the tetracycline-responsive promoter TET driving
lacZ gene expression (TET:lacZ). VE-cadherin:tTA 3 TET:lacZ
double transgenic mice expressed b-galactosidase in endothe-
lial cells in the skin in adult mice (Figure 2A). For these studies we
have used two lines of VE-cadherin:tTA, the D5 line with higher
expression and the D4 line with lower expression of tTA. In com-
bination with the same responder line carrying the TET:myrAkt1
transgene, D5 animals develop an overt vascular phenotype in
8–12 days after tetracycline withdrawal, while D4 animals re-
quire 6–7 weeks to produce a similar phenotype. We examined
the skin blood vessels of normal and double transgenic mice for
structural alterations and Akt signaling.
Necropsy of double transgenic mice after myrAkt1 induction
demonstrated marked changes in the vasculature in most or-
gans, most notably in the skin and subcutaneous fat, mammary
fat pads, visceral fat, retina, lungs, uterus, testes, and skeletalCANCER CELL AUGUST 2006
A R T I C L Emuscle. Many vessels in these mice became abnormally en-
larged and irregular with multifocal areas of ‘‘aneurysm’’ or ‘‘bal-
loon-like’’ enlargement (Figures 2B and 2C). The percentage of
the skin surface covered by blood vessels in double transgenic
mice was approximately twice that of wild-type control litter-
mates (37.029%6 8.092% versus 17.809%6 4.652%, respec-
tively; p < 0.01; controls n = 11; double transgenics n = 14).
Figure 2. Pathological blood vessel formation in double transgenic myrAkt1
mice
A: VE-Cadherin:tTA line drives expression of TET:lacZ reporter gene in adult
vasculature as shown by histology of the skin expressing b-galactosidase ac-
tivity (blue stain) in endothelial cells.
B–E: Whole tissue view of the flank skin of wild-type (WT) mice (B) and double
transgenic (DT) littermates (C). Corresponding histology sections of wild-
type (D) and double transgenic (E) skin taken at the same magnification
showing enlarged vessels in double transgenic skin. Cutaneous edema sep-
arating dermal collagen is shown (E, arrow). Note the increase in thickness
of double transgenic dermis from edema as indicated by a bar on the left
side of each panel.
F and G: One micrometer sections of blood vessels in wild-type (F) and dou-
ble transgenic (G) mice. MyrAkt1 expression induced enlarged vessels with
elongated endothelial cells and transluminal bridges (arrow).
H and I: Skin sections from wild-type (H) and double transgenic mice (I) were
analyzed for the presence of smooth muscle cells/pericytes by double
immunofluorescent staining with anti-SMA antibody (red) and BS-1 lectin
(green), which labels endothelial cells. Arrow in I shows enlarged vessel
with deficient SMA staining.
J–M: Increased levels of activated Akt in the vasculature in double trans-
genic myrAkt1 mice. Wild-type skin stained with FITC-lectin (J, green) to label
blood vessels, and anti-phosphorylated Akt antibody (K, red). The same
magnification of myrAkt1 double transgenic skin labeled with FITC-lectin
(L, green) and anti-phosphorylated Akt antibody (M, red).CANCER CELL AUGUST 2006The dermis and subcutaneous tissue were significantly thick-
ened as the result of edema in double transgenic mice (note ver-
tical bar covering the distance from the epidermis to the subcu-
taneous muscle layer) (Figures 2D and 2E). Edema was also
evident as separation of dermal collagen bundles (Figure 2E).
Edema was also present in other tissues, such as the lungs, re-
sulting in increased wet lung weight in double transgenic mice
compared to control mice (0.26 6 0.08 g versus 0.17 6 0.04 g,
respectively; n = 4 animals per group). There was substantial
accumulation of fluid in the pleural cavity in double transgenic
mice compared to controls (1.1 6 0.2 ml versus 0 ml, respec-
tively; n = 4 animals per group). Enlarged blood vessels were
lined with a single layer of elongated endothelial cells (Figures
2F and 2G). Some of these vessels contained structures previ-
ously described as ‘‘transluminal bridges’’ seen in ‘‘mother ves-
sels’’ (Dvorak, 2002; Pettersson et al., 2000) in response to
VEGF-A stimulation (Figure 2G, arrow). These bridges represent
endothelial cell cytoplasmic processes that project into and
across the vessel lumens and are thought to divide blood flow
into smaller-sized channels as ‘‘mother vessels’’ evolve into
‘‘daughter vessels.’’ Similar to the reported features of deficient
mural support in tumor blood vessels, many of these enlarged
vessels were partially deficient in mural cell coverage (i.e., peri-
cytes and smooth muscle cells). Figure 2H shows wild-type skin
with many small capillaries and a pair of larger vessels, both of
which were covered by a complete layer of smooth muscle actin
(SMA)-positivecells. Indouble transgenicmice, some largeSMA-
positive vessels persisted, but there were also enlarged vessels
deficient in mural cell coverage (Figure 2I, arrow). Tissues from
wild-type and double transgenic littermates were stained with
BS-1 lectin to highlight blood vessels and with antibodies to
pAkt. Skin vessels from wild-type mice were smaller in size and
had little activated Akt (Figures 2J and 2K). In contrast, pAkt
was strongly expressed in endothelial cells of enlarged blood
vessels in double transgenic mice (Figures 2L and 2M).
Sustained endothelial Akt activation leads to increased
blood volume and leaky blood vessels
We determined the changes in blood volume and vascular per-
meability in thewhole animal in double transgenicmice and con-
trol littermates by MRI following intravenous (i.v.) injection of the
contrast agent biotin-BSA-Gadolinium-DTPA (biotin-BSA-Gd-
DTPA). Intravascular contrast enhancement, as detected imme-
diately after administration of biotin-BSA-Gd-DTPA, was signif-
icantly lower in the double transgenic mice relative to control
mice (Figure 3A). The lower enhancement in double transgenic
mice corresponded to a significantly increased total blood
volume over which the same amount of contrast material distrib-
uted (p = 0.007) (Figure 3B). Blood volume in various tissues (in-
dicated by blood volume fraction [fBV]) was obtained from the
ratio of the contrast agent concentration in the tissue at time
zero to the concentration of the contrast agent in the vena
cava blood at time zero. The fBV in myrAkt1 double transgenic
mice was elevated in all tissues examined, including brain, hind-
limb, liver, and kidney, with statistically significant differences
seen in the brain and hindlimb of myrAkt1 mice compared to
control animals (brain, p = 0.005; limb, p = 0.003) (Figure 3C).
These findings are consistent with the increase in microvessel
diameter. The changes in fBV in the liver and the kidney were
not statistically significant due to large variance in mea-
surements. The changes in intravascular contrast material161
A R T I C L EFigure 3. MRI studies of the effects of endothelial myrAkt1 on blood volume and vascular permeability
A: Mice were taken off tetracycline for 7 days, then imaged by dynamic contrast enhanced MRI using intravenously administered biotin-BSA-Gd-DTPA. The
intravascular distribution of contrast agent in vivo is seen in overlay of maximal intensity projections maps from images that were taken prior to contrast
injection (gray) and immediately after contrast injection (color).
B: Total blood volume was significantly higher in myrAkt1 double transgenic mice than in control mice (p = 0.007; n = 6 mice per group).
C: Significant changes in blood volume fraction (fBV) were observed in the brain and hindlimb of double transgenic mice as compared to control mice (brain,
p = 0.005; hindlimb, p = 0.003; n = 6 mice per group).
D: Increased permeability surface area product (PS) was observed in the brain, limb, liver, and kidney, with statistically significant differences seen in the liver
(p = 0.01; n = 6 mice per group).
E and F: Edema is seen in skeletal muscles in double transgenic mice as shown by separation of muscle fibers in these mice (F) as compared to control mice (E).
Bars in graphs represent means 6 standard deviations.concentration over time were used as a way to assess vascular
permeability. As for most other macromolecules, the leakage
rate of biotin-BSA-Gd-DTPA across normal vessels was rela-
tively low. Hyperpermeable vessels would be expected to leak
contrast agent at a higher rate. The extravasation rate (indicated
by permeability surface area product [PS]) was calculated as the
rate of contrast accumulation in the tissues as a function of time.
Although a trend of higher permeability was seen inmany organs
in double transgenic mice, only the liver showed statistically sig-
nificant higher permeability over the course of 15 min (p = 0.01)
(Figure 3D). All tissues were harvested, fixed, and examined his-
tologically. In some organs, such as skeletal muscle, even
though quantitation of vascular leak in the relatively short time
period assayed by MRI was not dramatic (Figure 3D), clear evi-
dence of edemawas easily observed by separation in myofibers
in hematoxylin and eosin-stained sections (Figures 3E and 3F).
Wealsoemployedadditionalmethods toexplore vascular per-
meability in the vessels of double transgenicmice and control lit-
termates. Intravenous injection of the macromolecular tracer
dextran (70 kDa) conjugated to the fluorophore FITC allows one
to visualize alterations in vascular structure and vascular leak
after 2 hr. Abnormal blood vessels in double transgenic animals
were enlarged and irregularly shaped, and the extravasated
FITC-dextran left a perivascular fluorescent haze not observed
around normal vessels in wild-type mice (Figures 4A and 4B).
Edema can result from increased vascular permeability and
from defective lymphatic drainage. Therefore, we investigated162the functional status of lymphatics in double transgenic
mice. Evans blue dye, which binds albumin and allows us to
measure the extravasation of plasma proteins, was injected
i.v. Uptake of the dye in the intestine lymphatic network was
evident after 30 min in double transgenic mice, indicating
that blood vessels had leaked dye and lymphatic vessels
were functioning to reabsorb it (Figures 4C and 4D). We visu-
alized the structure of the lymphatics following injection of col-
loidal carbon in the terminal lymphatics in the ears of wild-type
and double transgenic mice. Colloidal carbon entered the lym-
phatics normally and revealed a normal pattern of lymphatic
valves and branching networks in both control and double
transgenic mice (Figures 4E and 4F). Electron microscopy
was used to investigate the structure of the enlarged blood
vessels in double transgenic mice. Examination of many endo-
thelial cell junctions in multiple skin sections from several dou-
ble transgenic and control animals did not reveal evidence of
junctional disassembly (Figure 4G). VVOs, structures that pro-
vide one pathway of transport of macromolecules across en-
dothelial cell membranes (Feng et al., 1996, 2000b), were nor-
mally present in the endothelial cells lining these vessels
(Figure 4H). The VVOs in double transgenic mice and wild-
type littermates were similar in number and ultrastructural
morphology. Although these findings do not conclusively de-
termine the cellular mechanism of vascular leak, they suggest
that VVOs are present and may to contribute to the edema
observed.CANCER CELL AUGUST 2006
A R T I C L EAcute versus chronic permeability in Akt1 null
and myrAkt1 transgenic mice
Vascular permeability can be quantified by measuring the
amount of Evans blue dye that leaks from otherwise equal vas-
cular beds into the surrounding tissue following a stimulus.
However, there is a basal level of transvascular flux of fluid
and protein that can be similarly quantified with longer measure-
ments than those needed to see permeability in response to
a stimulus. However, when the vascular beds are unequal, other
factors contribute to the final quantity of Evans blue accumula-
tion in the tissue besides ‘‘permeability’’ of the endothelium, in-
cluding vascular density and overall endothelial surface area.
We will suggest that the molecular pathways for the rapid ex-
travasation of Evans blue to stimuli such as VEGF-A and the
more gradual leakage that occurs over longer periods of time
Figure 4. Sustained endothelial Akt activation leads to structural and func-
tional changes
A and B: Vascular permeability was assessed in wild-type (WT) and double
transgenic (DT) littermates. Confocal microscopic images of skin from
wild-type (A) and double transgenic (B) mice after FITC-dextran perfusion
for 2 hr. Arrows indicate extravasated FITC-dextran into the interstitial space.
C–F: Lymphatic structure and function were assessed in control and double
transgenic animals. Lymphatic function was demonstrated by Evans blue
dye extravasation and lymphatic uptake in wild-type (C) and double trans-
genic (D) mesentery. Inset inD shows higher magnification of mesenteric lym-
phatic (blue,arrow)and adjacentbloodvessels (red). Intralymphatic injection
of colloidal carbon (India ink) in the mouse ear highlights normal lymphatic
network (white arrows) in the ear skin in both wild-type (E) and double trans-
genic (F) mice. The blood vessels in double transgenic mice are enlarged
compared to the normal vascular pattern in control mice (black arrows).
GandH: Electron microscopic studies of double transgenic endothelial cells
demonstrate intact and closed intercellular junctions (G, arrows) and many
VVOs (H, arrows).CANCER CELL AUGUST 2006are different. For the sake of our discussion, we are distinguish-
ing these by the terms ‘‘acute’’ versus ‘‘chronic’’ permeability.
The acute vascular permeability response to VEGF-A is typically
measured in 15–30 min; however, if one waits long enough even
normal blood vessels allow Evans blue to extravasate. By 2–3 hr
the skin of the myrAkt1 transgenic mice was visibly more blue,
and by 24 hr even the wild-type mice were blue. To measure
this chronic leak of Evans blue, we quantified extravasation at
8 hr. Because we wished to minimize alternative explanations
for the increased extravasation, such as differences in endothe-
lial surface area, we used animals that had been removed from
tetracycline for 5 days and had very little change to the vessel
structure and number in order to attempt to separate between
the structural alterations in the blood vessels and the signaling
that could impact these measurements (Figure 5A). Even before
dramatic alterations in vessel structure and number were evi-
dent,weobservedsignificantly increasedextravasationof Evans
blue inmyrAkt1 double transgenicmice, whichwe interpreted as
a result of chronic vascular permeability (Figure 5B). The Evans
blue accumulation in the lungs is shown prior to extraction
(Figure 5C). To assess acute permeability in response to
VEGF-A, a Miles assay was performed following intradermal
injection of VEGF-A (Figure 5D). Extravasation of Evans blue
dye in double transgenic mice was not statistically different
from control animals (Figure 5E). Recent reports have demon-
strated that acute permeability to VEGF-A in a Miles assay was
blunted in the Akt12/2 mice (Ackah et al., 2005). We could not
find significant differences in permeability to Evans blue or to
alterations in the vascular structure of the Akt+/+, Akt1+/2, or
Akt12/2 mice (Figures 5F–5H). Taken together these data sug-
gest that Akt1 is required for acute permeability in response to
VEGF-A but that chronic Akt1 activation leads to low-level
chronic vascular leak accompanied by edema. Despite our at-
tempts to measure chronic permeability before the vasculature
had become significantly abnormal, we cannot rule out the pos-
sibility that this chronic permeability is secondary to Akt-induced
morphological changes including factors such as reduced peri-
cyte-endothelial interactions. The overall health and normal vas-
cular structure of the Akt1 null mice in combination with these
data contributes to our emerging hypothesis that Akt1 is critical
for pathological vascular responses but not for those regulated
in a physiological manner in healthy adult vascular homeostasis.
Plasticity of the adult vasculature in response
to induction followed by suppression
of sustained endothelial Akt signaling
In order to determine whether the vascular abnormalities in-
duced by myrAkt1 could be reversed, we first removed tetracy-
cline from the drinking water of double transgenic mice to in-
duce myrAkt1 expression, allowed the vascular phenotype to
become fully developed, and then restored tetracycline. These
animals without tetracycline became sickly, with marked edema
and fluid accumulation making the animals appear fat, with
ruffled fur, nearly closed eyelids, and vascular anomalies in the
ears (Figure 6B) and flank skin (Figure 6F). Even in our lower ex-
presser D4 line, in which the phenotype developed slowly over
6–7 weeks, the vascular abnormalities were still reversible.
Within a matter of days following readministration of tetra-
cycline, a general resolution of fluid and healthy appearance
returned. The samemouse shown in Figures 6A and 6B now ap-
pears healthy, with a normal-appearing slim body, smooth hair,163
A R T I C L EFigure 5. Baseline vascular permeability is increased in double transgenic
myrAkt1 mice but not in Akt1 null mice
A–C: Wild-type (WT) and double transgenic (DT) mice were taken off tetra-
cycline for 5 days prior to analysis of baseline permeability. Evans blue dye
(50 mg/kg) was injected i.v. and allowed to circulate for 8 hr, at which
time the animals were sacrificed and various organs were collected for
analysis. Relatively normal skin vasculature in wild-type and double trans-
genic mice is shown inA. Evans blue dye was extracted from various organs,
and the amount of extracted dye was measured by spectrophotometric
absorbance at 620 nm (B). Lungs from WT and DT mice 8 hr after Evans
blue injection (C).
D and E: Miles assay in WT and DT mice that were off tetracycline for 5 days.
Evans blue dye was injected in the tail vein. Saline or VEGF-A was immedi-
ately injected intradermally in the back skin (D). Quantification of Evans
blue dye extracted from the skin (E).
F–H: Baseline vascular permeability in Akt12/2 mice and control littermates
was determined as described in A. F: Whole lungs taken from Akt1+/+ and164and open eyes, although the vascular anomalies in the ears were
still apparent (Figure 6C). After 4 weeks back on tetracycline, the
vascular anomalies had largely disappeared (Figures 6D and
6G). These results demonstrate the enormous ‘‘plasticity’’ of
the microvasculature in the adult animal in response to the in-
duction or suppression of endothelial Akt signaling.
Induction of myrAkt1 expression in endothelial cells
leads to activation of Akt and its canonical
downstream effectors
To investigate the signaling pathways downstream of Akt in our
animal model, we isolated primary endothelial cells from double
transgenic animals. Culture purity was assessed by uptake of
DiI-acetylated LDL and immunoreactivity to CD31 (Figures
S2A–S2C). There were enhanced levels of pAkt in the absence
of tetracycline but no changes in the levels of other signaling
pathways also activated by VEGF, such as phosphorylated
Erk-1/2 (Figure S2D). Moreover, myrAkt1 expression was asso-
ciated with activation of downstream signaling pathways, as
evidenced by increased phosphorylation of mTOR, GSK-3b,
and eNOS (Figure S2E). Total levels of these proteins were un-
changed by tetracycline conditions and myrAkt1 expression.
Taken together, these data demonstrate the specificity of
myrAkt1 in inducing Akt signaling pathways in double transgenic
endothelial cells.
Investigation of eNOS in VEGF-A-induced acute
permeability and myrAkt1-induced chronic permeability
We investigated the contribution of eNOS activation to the mor-
phological and functional changes in double transgenic animals.
VEGF-A-induced vascular permeability in endothelial cells has
been shown to be dependent on eNOS activity. However, a
correlation to vascular morphology has not been reported. To
explore the potential role of eNOS in mediating the effects of
myrAkt1, we treated double transgenicmice andwild-type litter-
mates with antennapedia-caveolin-1 peptide (AP-Cav), an in-
hibitor of eNOS that does not block nNOS, iNOS, or Src phos-
phorylation (Bucci et al., 2000; Gratton et al., 2003). Daily
dosing of the AP-Cav peptide reduces tumor-associated
eNOS activity and tumor progression (Gratton et al., 2003). We
confirmed that administration of AP-Cav blocked VEGF-A-
induced permeability using the Miles assay as previously re-
ported (Gratton et al., 2003). We used a dose of AP-Cav that
was shown to be sufficient to block VEGF-A-induced vascular
permeability and tumor growth in vivo. In the Miles assay,
mice were pretreated with either AP-Cav peptide or control an-
tennapedia peptide without the active caveolin-1 domain (AP)
for 45 min prior to intravenous administration of the tracer Evans
blue dye. To induce vascular permeability, either saline or VEGF-
A was injected intradermally in the mouse ear. After 30 min,
there was increased extravasation of Evans blue dye in re-
sponse to VEGF-A in mice pretreated with control AP peptide
(Figure S3A). In contrast, VEGF-A did not increase Evans blue
extravasation in mice pretreated with AP-Cav, demonstrating
that AP-Cav was effective in blocking VEGF-A-induced vascular
Akt12/2mice 8 hr after Evans blue injection.G:Quantitation of extravasated
Evans blue in various organs from Akt1+/+, Akt1+/2, and Akt12/2mice. H: Nor-
mal vasculature is seen in the flank skin in these mice. Data from all the ex-
periments above represented four mice per group and were calculated
as micrograms of dye per gram tissue weight (mean 6 SEM). p value <
0.05 was considered statistically significant. NS is not statistically significant.CANCER CELL AUGUST 2006
A R T I C L EFigure 6. Reversibility of the vascular phenotype in double transgenic myrAkt1 mice
A–D: The same double transgenic mouse was followed over a time course of tetracycline administration. Images of the whole body and ear are shown for the
mouse raised to maturity on tetracycline (A), followed by tetracycline withdrawal for 7 weeks (B), then back on tetracycline for 6 days (C) and 4 weeks (D).
E–G: The normal cutaneous vasculature in similarly treated representative double transgenic mice (E) was dramatically altered in response to tetracycline
withdrawal (F). Restoration of a near-normal vascular pattern was observed when these animals were placed back on tetracycline for 4 weeks (G).permeability. The differences in Evans blue extravasation be-
tween AP- and AP-Cav-treated animals were statistically signif-
icant (Figure S3B).
To determine whether eNOS mediates myrAkt1-induced
chronic permeability, wild-type and double transgenic myrAkt1
littermates were taken off tetracycline and injected intraperito-
neally (i.p.) with AP-Cav or AP peptides each day for 7 days us-
ing a protocol that was efficacious in reducing tumor growth and
permeability (Gratton et al., 2003). On day 8 of the study, the
mice were injected intravenously with the macromolecular
tracer FITC-dextran to perfuse the vasculature. After 2 hr, the
flank skin was harvested and analyzed by confocal microscopy
for extravasation of FITC-dextran. AP-Cav, at concentrations
that effectively inhibit eNOS in vivo (Gratton et al., 2003), did
not block the development of pathological blood vessel mor-
phology or vascular permeability in myrAkt1-expressing mice
(Figures S3D and S3H compared to Figures S3E and S3I). Sim-
ilar results were obtained when the dose of AP-Cav was dou-
bled, or when N-nitro-L-arginine methyl ester (L-NAME), a struc-
turally different eNOS inhibitor, was used (Figure S3F). Thus, we
cannot find an indication of eNOS requirement in myrAkt1-
induced structural alterations or chronic permeability.
Rapamycin blocks pathological blood vessel
formation and vascular permeability
Rapamycin is a highly specific inhibitor of mTOR that is also an
immunosuppressant that is under investigation as an anticancer
therapy (Bjornsti and Houghton, 2004). Studies using rapamycin
have suggested that it may be antiangiogenic (Guba et al.,
2002). To determine whether the mTOR inhibitor rapamycin in-
hibits vascular permeability induced by VEGF-A, we pretreated
Nu/Nu mice with rapamycin or control solvent for 24 hr prior to
performing aMiles assay.We observed increased extravasation
of Evans blue dye in response to VEGF-A inmice pretreated with
control solvent but not in mice pretreated with rapamycinCANCER CELL AUGUST 2006(Figures 7A–7C). This demonstrated that rapamycin was effec-
tive in blocking VEGF-A-induced acute vascular permeability
in a normal vasculature. To determine whether rapamycin in-
hibits the formation of pathological blood vessels in double
transgenic myrAkt1 mice, the mice were taken off tetracycline
and on the same daywere injected i.p. with rapamycin or vehicle
for 7 days. Treatment with rapamycin almost completely
blocked the formation of pathological blood vessels in myrAkt1
transgenic mice (Figures 7D–7F). Rapamycin also blocked the
extravasation of FITC-dextran (Figures 7G–7I). Necropsy exam-
ination of rapamycin-treated mice showed that these animals
did not develop tissue edema or pleural fluid.
Surprisingly, in myrAkt1-expressing endothelial cells derived
from double transgenic mice, rapamycin reduced pAkt levels
(Figure 7J). Similarly, treatment with rapamycin was also found
to inhibit pAkt levels in kidneys of both wild-type and double
transgenic mice (Figure 7K). To determine whether the anti-
pAkt effects of rapamycin were independent of myrAkt1, we
performed dose response studies in primary endothelial cells
isolated from human skin. After 3 days we observed an increase
in pAkt levels with 1–4 ng/ml rapamycin, followed by a dose-
dependent decrease from 10 to 50 ng/ml (Figure 7L). To deter-
mine whether the effects of rapamycin on pAkt were within the
range of rapamycin given to patients, we performed a dose
response study on wild-typemice and correlated the blood con-
centrations of rapamycin to the effects on phosphorylation of
Akt and S6 Kinase, a downstream molecule activated by
mTOR. Mouse blood was analyzed for rapamycin levels by our
clinical lab, where similar assays are performed on blood sam-
ples from patients treated with rapamycin. We found that treat-
ment of mice with rapamycin in the dose range of 0.5 mg/kg
(7.1 6 0.1 ng/ml trough blood levels) to 1 mg/kg (16.9 6 6.2
ng/ml trough blood levels) matched the optimal trough blood
levels of 6–15 ng/ml in humans (Meier-Kriesche and Kaplan,
2000). At this dose we have decreased pS6 Kinase and pAkt165
A R T I C L EFigure 7. Effects of rapamycin on pathological vessel formation in double transgenic myrAkt1 mice
A–C: Effects of rapamycin on VEGF-A-induced vascular permeability. Athymic Nu/Nu mice were pretreated with either solvent (A) or rapamycin (4 mg/kg,
intraperitoneal) (B) for 24 hr prior to intravenous injection of Evans blue dye. Immediately following Evans blue injection, saline or VEGF-A was injected intrader-
mally in the ears and back skin. Photographs of extravasated Evans blue in the ears of treated animals are shown. Quantitation of Evans blue dye extracted
from the ears and skin (C). Data represent five to six mice per rapamycin- or solvent-treated group, three sites per saline or VEGF-A treatment, and were cal-
culated as micrograms of dye per gram tissue weight (mean 6 SEM). p value < 0.05 was considered statistically significant. NS, not statistically significant.
D–I:Wild-type (WT) and double transgenic (DT) littermates were taken off tetracycline to induce myrAkt1 expression. Starting on the same day, they were given
daily intraperitoneal injections of rapamycin or solvent for 7 days. On day 8, the mice were perfused intravenously with FITC-dextran for 60 min, and the flank skin
was examined (D–F) (whole tissue view, magnification32.5) and harvested for confocal microscopy (G–I) (magnification3200). Extravasation of FITC-dextran
from the blood vessels in solvent-treated DT mice is shown in H (arrows).
J:Double transgenic endothelial cells were treated for 48 hr6 tetracycline6 rapamycin and analyzed by Western blot for phosphorylated Akt and expression
of HA-tagged myrAkt1 transgene.
K: Control (C) and double transgenic myrAkt1 mice were taken off tetracycline and starting on the same day injected intraperitoneally with rapamycin for 4
days. The animals were sacrificed and the kidneys were harvested and analyzed by Western blot for phosphorylated and total Akt.
L: Primary human dermal microvascular endothelial cells were treated with rapamycin (1–50 ng/ml) for 3 days and analyzed by Western blot for phosphory-
lated and total Akt.
M: Inbred FVB mice were injected intraperitoneally with rapamycin (0.1–4 mg/kg/day) for 4 days. The animals were sacrificed, and the kidneys were harvested
and analyzed by Western blot.levels in whole kidney lysates after 4 days (Figure 7M). Our find-
ings suggest that long-term treatment with rapamycin may be
an effective ‘‘Akt inhibitor’’ of endothelial cells, and perhaps of
other normal cells in vitro and in vivo.
Rapamycin reduces tumor growth
and tumor vascular permeability
Rapamycin is known to inhibit tumor growth and tumor angio-
genesis (Guba et al., 2002). We investigated whether rapamycin
treatment also affects tumor vessel permeability. VEGF-A-ex-
pressing C6 rat glioma cells were inoculated subcutaneously
into Nu/Numice, allowed to grow to approximately 0.1 cm3, and
then treated with either control solvent or rapamycin for 4, 9, and
12 days. Treatment of the animals with rapamycin did not influ-
ence normal bodily functions and behavior such as weight gain,
appetite, or grooming behavior. Similar to the published studies,
rapamycin significantly reduced tumor growth after 7 days in
Nu/Nu mice (Figure 8A). The final tumor volumes at day 12166were 1.49 6 0.49 cm3 (solvent) and 0.40 6 0.18 cm3 (rapamy-
cin). Statistically significant reductions in C6 tumor growth
were also observed after 8 days of drug treatment at much lower
doses of rapamycin, for example, compared to solvent, which
had tumor volumes of 1.10 6 0.82 cm3, at 0.5 mg/kg/day, the
volumes were 0.37 6 0.23 cm3, and at 1 mg/kg/day they were
0.32 6 0.15 cm3 (n = 6 tumors/group). Tumor vascular perme-
ability was assayed by i.v. injection of Evans blue dye as previ-
ously reported (Gratton et al., 2003). Evans blue in the tumor
tissue was significantly reduced after 12 days of rapamycin
treatment (Figure 8B). In contrast to our observations of normal
kidneys and primary human endothelial cells, Western blot of to-
tal tumor tissue lysates indicated that rapamycin effectively in-
hibited mTOR signaling (indicated by decreased S6 Kinase
phosphorylation) but increased pAkt levels in the total tumor ly-
sates (Figure 8C). We attribute this increase in pAkt levels to the
effects of rapamycin in increasing pAkt in tumor cells rather than
stromal cells, as tumor cells make up most of the cellular massCANCER CELL AUGUST 2006
A R T I C L EFigure 8. Effects of rapamycin on C6 rat glioma tumor
A: Athymic Nu/Nu mice were injected subcutaneously with C6 rat glioma cells expressing VEGF-A. Tumors were allowed to grow tow0.1 cm3 before random-
ization into solvent or rapamycin (4 mg/kg/day) treatment group. Tumor size was measured every 2–3 days with a caliper. Tumor growth is presented as the
mean 6 SD, n = 4 mice per treatment group, two tumor sites per mouse. p values were obtained by comparison with solvent-treated group.
B: The mice in A were injected with Evans blue dye (50 mg/kg, i.v.) and allowed to circulate for 30 min before perfusion with 100 cc of saline to clear intravas-
cular Evans blue. Tumors were resected and Evans blue content was quantified (n = 4 mice per treatment group). p values were obtained by comparison with
solvent-treated group.
C: Nu/Nu mice bearing C6 tumors were treated6 rapamycin (0.5 or 1.0 mg/kg/day) for 8 days. Tumors were harvested for Western blot analysis of phosphor-
ylated and total S6 kinase and Akt.
D and E: Frozen sections of C6 tumors fromCwere immunostained for phosphorylated Akt (red) and CD31 (green) to label blood vessels. Nuclei were counter-
stained with Hoechst dye (blue). Arrows indicate endothelial cell nuclei positive for phosphorylated Akt in solvent-treated tumors (D) and loss of phosphory-
lated Akt in endothelial cells in rapamycin-treated tumors (E). Magnification 3200.of this tumor. This interpretation was further supported by im-
munohistochemistry with anti-CD31 antibodies to label endo-
thelial cells (green), anti-pAkt antibodies (red), and Hoechst
dye to label nuclei (blue) (Figures 8D and 8E). In solvent-treated
animals, pAkt was detected at high levels in both tumor cells and
blood vessels, but in the rapamycin-treated animals, pAkt levels
in tumor blood vessels were clearly reduced in comparison to
the surrounding tumor. While overall pAkt levels from sample
to sample cannot be accurately assessed by this method, we
can conclude that the response of the vascular stroma com-
pared to the adjacent tumor was a dramatic relative decrease
in endothelial pAkt levels. These data suggest that clinically rel-
evant doses of rapamycin decrease tumor growth, decrease Akt
signaling in the vascular stroma, but at least in C6 glioma in-
crease pAkt signaling in the tumor. Additional studies are
needed to determine whether decreases in tumor growth are
strictly due to antiangiogenic effects, or to both antiangiogenic
and antitumor effects that result from loss of downstream
mTOR signaling irrespective of pAkt signaling. Similarly, more
tumor studies are needed to determine if the increase in pAkt
levels in C6 tumors following rapamycin treatment is represen-
tative of all tumor types or varies from tumor to tumor.CANCER CELL AUGUST 2006Discussion
Unlike the normal vasculature, vessels found in solid tumors are
irregularly shaped, enlarged, tortuous, leaky, and often deficient
in normal pericyte interactions. These features are recapitulated
by VEGF-A overexpression in tumors and in nontumor tissues
(Dvorak, 2003). We have shown that chronic activation of endo-
thelial Akt signaling alone is sufficient to induce these patholog-
ical vessels in a nontumor microenvironment. In our model, we
have used a myristoylated Akt1 transgene, the major isoform
in endothelial cells. In the recent study by Ackah et al., Akt1
null micewere used in amodel of hindlimb ischemia. In response
to VEGF-A administration, both angiogenesis and acute perme-
ability were blunted (Ackah et al., 2005). This is consistent with
the work of many investigators in vitro and in vivo, with the
exception of a recent publication where permeability was
assessed in a Matrigel plug assay (Chen et al., 2005). In that
model, blood vessel invasion into Matrigel can be accompanied
byhemorrhagedependingon theexperimental conditions.How-
ever, since Akt1 null mice have a clotting defect (Chen et al.,
2004) and platelet clotting can play an important role in prevent-
ing hemorrhage during angiogenesis (Kisucka et al., 2006), it is167
A R T I C L Epossible that the resultant bloody plug and the extravasation of
Evansblue observedweredue to hemorrhage rather than vascu-
lar permeability. Our model differs from those of the Akt1 null
mice where all cells are deficient for Akt1 and allows us to exam-
ine endothelial cell autonomous signaling. Our data are consis-
tent with many studies that report proangiogenic effects of
Akt1, and the antiangiogenic effects on vascular function that
we observed with rapamycin in mice further support our conclu-
sions.However,wecannot rule out thepossibility thatmyrAkt1 in
our model may function to mimic other isoforms or have some
other unknown functions not attributable to endogenous Akt1.
The hypothesis that Akt1 is more critical for pathological angio-
genesis than vascular homeostasis is also similar to what has
been observed in the Akt1 null mice with respect to glucose ho-
meostasis (Chen et al., 2001; Cho et al., 2001a).
Our data also shows that the pathological vessels induced by
myrAkt1 require sustained Akt signaling for their maintenance
even when minimal overexpression in the D4 line is accompa-
nied by gradual angiogenesis over the course of 7 weeks. This
is reminiscent of the continued reliance of tumor blood vessels
on VEGF-A where removal of VEGF-A in tumor blood vessels
leads to regression of newly formed blood vessels (Benjamin
et al., 1999; Benjamin and Keshet, 1997). Similarly, ‘‘mother ves-
sels’’ inducedbyadenoviral vectors expressingVEGF-A, and the
dramatic vascular alterations in multiple organs following VEGF-
A overexpression, all regress as VEGF-A levels decline (Dor
et al., 2002; Nagy et al., 2002; Ozawa et al., 2004; Pettersson
et al., 2000). Even some normal vascular beds retain a depen-
dence on VEGF-A (Kamba et al., 2005). These data combined
demonstrate the fragility of pathological blood vessels after
VEGF-A overexpression. The fragility of Akt-induced blood ves-
sels, even after long periods of time, underscores our hypothesis
that Akt signaling downstream of VEGF-A may be mediating
many of the VEGF-A-associated phenotypes and strengthens
the rationale for Akt inhibition to decrease angiogenesis and ex-
cessive vascular permeability in cancer. Although it is beneficial
for tumor blood vessels to be permeable to chemotherapy and
other drugs, excess vascular leak leads to increased interstitial
pressure, which is counterproductive for drug delivery. Thus,
the desire for vascular normalization has become an important
consideration in antiangiogenic therapy (Jain, 2005).
A major phenotype of endothelial myrAkt1-expressing mice is
extensive tissue edema, most notably in the skin, soft tissues,
and pleural space accompanied by eventual respiratory failure.
Rapamycin was able to prevent VEGF-induced acute perme-
ability and the development of pathological blood vessels and
edema in double transgenic mice. However, the eNOS inhibitor
AP-Cav only reduced acute vascular permeability in response to
VEGF-A. This acute response has been previously thought to be
mediated primarily by Akt to eNOS signaling (Bucci et al., 2000;
Bucci et al., 2005; Fulton et al., 1999; Six et al., 2002).Whether or
not there is a direct role of signaling downstream of mTOR in
vascular permeability, or these findings are simply the result of
rapamycin-induced Akt loss, remains to be determined. Differ-
ent molecular pathways for acute and chronic vascular leak
may explain why Akt-induced chronic permeability is less re-
sponsive to eNOS inhibitors. Similarly, we might have expected
that chronic Akt activation in our animals would result in a loss of
responsiveness to VEGF-A-induced acute permeability. Not
only did we get a normal VEGF-A response in myrAkt1 trans-
genic animals, but it was notable that we did not get an elevated168response. Future studieswill be focusedondeterminingwhether
chronic vascular leak is dependent on downstream pathways in
response toAkt activation. Edema is a significant complication in
many cancers that is contributed by tumor vascular leak as well
as complicated by surgical damage to local lymphatics. The use
of MRI for assessing vascular burden and vascular leak could be
adapted to investigate the efficacy of antiangiogenic therapy
in patients, especially in anti-VEGF-A-based therapy, which
should similarly decrease tumor vessel leakage.
Feedback regulation of Akt by mTOR has recently been re-
ported (Sarbassov dos et al., 2005). These studies show that
the rictor-mTOR complex can phosphorylate Akt, thus making
mTOR both downstream and upstream of Akt. Although this
complex is rapamycin insensitive and the preferential reduction
in mTORC1 by rapamycin results in increased Akt phosphoryla-
tion in short-term treatment, long-term treatment with rapamy-
cin has been shown to partially inhibit Akt activation (Edinger
et al., 2003). It has been demonstrated that rapamycin-based
pAkt inhibition can be explained by an increasing sequestration
of mTOR by rapamycin with secondary consequences on the
assembly of mTORC2 (Sarbassov dos et al., 2006). Consistent
with the proposed model, at lower rapamycin doses in culture
we find elevation of pAkt, which steadily diminishes as the con-
centration of rapamycin is increased. In a recent study, rapamy-
cin used at 10 mg/kg decreased pAkt levels in xenograft tumors
(Sarbassov dos et al., 2006). We found that rapamycin doses
between 0.5 and 1 mg/kg provide the recommended clinical
blood levels and lead to tumor growth inhibition and stromal
suppression of pAkt, but elevation of tumor pAkt. Consistent
with our findings, it has been reported that some human cancer
cell lines and cancer patients in rapamycin-based clinical trials
have elevated tumor levels of pAkt in response to rapamycin
(O’Reilly et al., 2006). This may suggest that differences re-
ported in the literature on tumor cell Akt responses can be
dose related. If human tumors do indeed depend on sustained
endothelial Akt signaling to induce pathological blood vessel
formation, our findings suggest that rapamycin treatment may
be antiangiogenic via inhibition of endothelial Akt activation. Ex-
trapolation of these findings may suggest that, in addition to re-
ducing tumor vascularization, rapamycin treatment may reduce
tumor vascular leak and interstitial pressure, and perhaps asci-
tes accumulation and edema in some cancer patients. There
have been concerns over using an immunosuppressant in can-
cer treatment, with the possibility that debilitating the immune
system may work against the host’s ability to fight cancer and
infections. Interestingly, one study reported a decrease in
Kaposi’s sarcoma in renal transplant patients receiving rapamy-
cin for immunosuppression (Stallone et al., 2005). Whether or
not this protection will extend to nonvascular tumors remains
to be determined. Clearly, rapamycin is an exciting therapy
that should be further explored in cancer treatment as an antian-
giogenic agent as well as an effective vascular Akt inhibitor.
Experimental procedures
Mice
The double transgenic mouse model that expresses myrAkt1 in endothelial
cells under tetracycline control has been previously described (Sun et al.,
2005). The Akt2/2 mice were kindly provided by Dr. Morris Birnbaum (Cho
et al., 2001b). All studies were conducted in compliance with the Beth Israel
Deaconess Medical Center IACUC guidelines.CANCER CELL AUGUST 2006
A R T I C L EInhibitor studies
Mice were given daily i.p. injections of rapamycin (0.1–4 mg/kg) (LLC Labo-
ratories), NG-nitro-L-arginine methyl ester (L-NAME, 25 mg/kg/day), anten-
napedia-caveolin-1 peptide (AP-Cav, 2.5 mg/kg/day), control antennapedia
peptide (AP, 1.2mg/kg/day), or vehicle controls. Rapamycinwas dissolved in
solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in ster-
ile H2O). L-NAME was dissolved in PBS. AP-Cav and AP peptides were pre-
pared as stock solutions in DMSO and then dissolved to a final concentration
in sterile H2O.
Details of the analysis for tumor growth and vascular function can be found
in the Supplemental Data.
MRI analysis
Double transgenic mice and control littermates were taken off tetracycline for
7 days to induce myrAkt1 expression prior to MRI scan. The macromolecular
contrast material biotin-BSA-Gadolinium-DTPA (biotin-BSA-Gd-DTPA) was
prepared as previously reported (Dafni et al., 2002). Details can be found in
the Supplemental Data.
Histology and immunohistochemistry
Frozen and paraffin embedded tissues were processed by standard
methods. For evaluation of VVOs, skin tissues were harvested and pro-
cessed for electron microscopy as previously described (Dvorak et al.,
1996). Details for lacZ staining and immunohistochemistry are provided in
the Supplemental Data.
Isolation of primary human and mouse endothelial cells
Human dermal microvascular endothelial cells (HDMEC) were isolated from
neonatal foreskin as previously described (Richard et al., 1998). Use of
human tissue was approved by the Beth Israel Deaconess Medical Center
Institutional Review Board. Mouse endothelial cells were isolated from
hearts. See Supplemental Data for details.
Statistical analysis
Results were presented as mean 6 SD or SEM. Statistical significance of all
data was analyzed using InStat 3.0 (GraphPad Software, Inc.). p values %
0.05 in unpaired two-tail Student’s t test were considered to be statistically
significant.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
three supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/10/2/159/DC1/.
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